03:54 PM EDT, 03/23/2026 (MT Newswires) -- Health care stocks rose late Monday afternoon with the NYSE Health Care Index up 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.2%.

The iShares Biotechnology ETF (IBB) rose 0.9%.

In corporate news, Gilead Sciences ( GILD ) is nearing an acquisition of autoimmune-disease-focused biotech Ouro Medicines for up to $2 billion, The Financial Times reported. Gilead shares were up 0.3%.

Insmed ( INSM ) shares jumped past 5% after it said a phase 3b trial of Arikayce as part of a multidrug regimen to treat patients with Mycobacterium avium complex lung infection who have not started antibiotics has met its primary and secondary endpoints.

Cencora ( COR ) agreed to buy EyeSouth Partners' retina business for $1.1 billion. Cencora ( COR ) shares were down 1.6%.

Apogee Therapeutics ( APGE ) shares surged 21% after 52-week maintenance data from part A of its phase 2 trial of zumilokibart in people with moderate-to-severe atopic dermatitis showed durable maintenance response and "deepening" response for lesional and itch endpoints.